Naked RNA cannot bind to the cell surface for delivery. Its size and negative charge prevent it from passing through the hydrophobic barriers of cell membranes. To deliver intact, therapeutic RNA into the cytoplasm, scientists must overcome three formidable barriers:
Extracellular Degradation In the bloodstream, naked RNA is rapidly degraded by extracellular RNases, and it rarely reaches target tissues. Protective carriers, such as lipid nanoparticles (LNPs), shield RNA from this degradation.
The Endosomal Entrapment Challenge: Cells take in RNA via endocytosis, enclosing the protective nanoparticle inside an endosome. However, over 99% of RNA therapeutics become trapped and broken down there, never reaching the cytoplasm where they are needed. The Endosomal Escape Dilemma: RNA must escape the endosome before it fuses with a lysosome. Delivery systems must remain stable in the bloodstream while also breaching the endosomal membrane and releasing their RNA cargo.
Researchers are constantly developing new chemical strategies such as LNPS to delivery vectors to help therapeutic RNAs escape the endosome and reach their intended targets. Lipid nanoparticles (LNPs) have become the gold standard for delivering RNAi therapies such as siRNA, boasting encapsulation efficiencies above 90% and powerful gene silencing effects, especially in the liver. The success rate of RNAi delivered via LNPs is best validated by landmark clinical outcomes and formulation benchmarks:
Clinical Success Rate: Examples (Patisiran / Onpattro)
The clinical viability of LNP-mediated RNAi is led by Onpattro, an FDA-approved LNP-siRNA therapeutic for hereditary transthyretin (TTR) amyloidosis.
Payload Efficacy: Intravenous LNP delivery achieves a rapid, sustained reduction of target serum TTR levels by about80% to 87%.
Clinical Improvement: In the APOLLO trial, 56% of treated patients showed improvements in neurological impairment (mNIS+7 scores) at 18 months, compared to only 4% in the placebo group.
Disease Modification: Patients demonstrated an 89% to 94% reduction in the rate of physical and quality-of-life decline compared to historical placebo baselines.
Long-Term Efficacy: Five-year data show that continued LNP-RNAi treatment maintains survival and stabilizes neuropathy.
Lipid nanoparticles (LNPs) are being use for these RNA molecule: RNA interference (RNAi), small interfering RNA (siRNA), and messenger RNA (mRNA).
For an RNA molecule to work well within an LNP delivery system, it generally requires the following: Larger RNA molecules, such as mRNA, naturally carry a greater net negative charge. This helps them complex more efficiently with the ionizable cationic lipids in the LNP. The result is higher encapsulation efficiency and stable particle formation. To prevent the RNA payload from triggering an immune response or degrading too quickly inside the body, mRNA is usually engineered with modified nucleotides. Self-Amplifying RNA (saRNA): A larger, specialized variant of mRNA that not only codes for a target protein but also copies itself inside the cell. This allows for prolonged protein expression and enables highly effective dosing at lower amounts.
For viral delivery, positive-sense single-stranded RNA [(+)ssRNA] and self-amplifying RNA work best because they resemble host messenger RNA (mRNA).
This allows the host cell’s ribosomes to translate them immediately upon entry into the cytoplasm, making them highly efficient for gene therapies, vaccinations, and protein expression.
1. Messenger RNA (mRNA) : Encodes specific proteins. Upon delivery, the host cell machinery translates it directly into the desired therapeutic protein. Vaccine development and protein-r: It does not integrate into the host cell’s genome, lowering the risk of insertional mutations.
2. Self-Amplifying RNA (saRNA) / Replicons Based on the genomes of positive-sense RNA viruses (like alphaviruses). Once inside the cell, it uses its own viral RNA-dependent RNA polymerase to replicate its own RNA.
3. Short Interfering RNA (siRNA) and Short Hairpin RNA (shRNA). These are double-stranded RNA molecules designed to interface with the cell’s natural RNA interference (RNAi) pathway to degrade specific target messenger RNAs. “Gene silencing” applications, such as turning off disease-causing genes, inhibiting cancer growth, or acting as an antiviral therapy.
Viral Genome Vectors The actual genetic code of the virus itself (e.g., retroviruses, lentiviruses, adenoviruses) is engineered to carry the specific RNA cargo. High-efficiency, targeted delivery into dividing or non-dividing host cells. Using RNA instead of DNA for delivery avoids the risk of genetic material integrating into the host’s permanent DNA. When delivered via lipid nanoparticles (LNPs) or engineered viral capsids, positive-sense molecules can harness cellular machinery to perform specific, transient tasks without genome modification. For viral delivery of RNA (e.g., retroviruses, lentiviruses, AAV), CMC assay panels must rigorously characterize both the viral vector and the packaged RNA payload.
RNA Payload Characterization (Drug Substance) will use Next-Generation Sequencing (NGS) or RT-PCR to verify the RNA sequence, transgenes, and regulatory elements. Capillary electrophoresis (CE) or analytical HPLC will check for fragmented RNA. Ribogreen assays measure both total and encapsulated RNA to ensure proper dose calculation.
Viral Vector Characterization (Drug Product)Use qPCR or ddPCR to quantify Vector Genomes (VG/mL) and cell-based infectivity or transduction assays to determine Infectious Units (IU/mL). HPLC verifies the ratio of full capsids (containing RNA) to empty capsids (lacking RNA or containing truncated variants). Mass spectrometry, peptide mapping, or ELISA confirm the serotype and capsid protein composition. Dynamic Light Scattering (DLS) or Nanoparticle Tracking Analysis (NTA) measures particle size distribution, polydispersity, and zeta potential.
Safety & Purity Replication-Competent Viruses (RCL/RCV): Cell-based assays ensure the viral vector cannot replicate in the patient. ELISA for Host Cell Proteins (HCP) and qPCR for Host Cell DNA (HCD). Compendial USP/EP testing for bacterial, fungal, and mycoplasma contamination. In vitro and in vivo viral screening assays rule out broader viral contamination. Endotoxins: Limulus Amebocyte Lysate (LAL) test measures pyrogen levels. Potency MOA: In vitro cell-based bioassays to demonstrate target gene expression (e.g., flow cytometry or ELISA) or biological activity (e.g., target cell lysis) following transduction.
AOC for RNA-based drug delivery
Small interfering RNA (siRNA) and Antisense Oligonucleotides (ASOs) are most effective as therapeutic payloads in Antibody-Oligonucleotide Conjugates (AOCs). These RNA molecules help the cell reduce or silence harmful gene expression.
The type of RNA used depends on the disease being targeted:
- siRNA (Small Interfering RNA): This type is effective at targeting specific mRNAs. Its double-stranded structure and small size make it stable in the body. siRNA is often linked to antibodies that target transferrin receptor 1 (TfR1) to treat neuromuscular diseases such as myotonic dystrophy.
- ASOs (Antisense Oligonucleotides): These are synthetic, single-stranded RNA or DNA sequences. They are effective when designed to bind to nuclear RNAs, pre-mRNAs, or harmful non-coding RNAs to fix splicing or trigger degradation.
- Aptamers: These folded, single-stranded RNA molecules can act as therapeutics on their own. They can also serve as targeting ligands or help deliver other RNA payloads directly into cells.
These RNA types are preferred because they are modular, structurally robust, and can be chemically modified to survive within target cells. For AOCs delivering RNA (such as siRNA, ASOs, or PMOs), CMC uses several tests to assess the identity, purity, integrity, conjugation efficiency, and potency of the product. These tests check how the RNA is attached to the antibody through the linker. The Drug-to-Antibody Ratio (DAR) indicates the average number of RNA molecules per antibody. The tests also look at the distribution of different conjugate products.
- Conjugation Site & Stoichiometry: These tests confirm that the RNA attaches at the intended amino acids, such as engineered cysteines or surface lysines. Methods include Liquid Chromatography-Mass Spectrometry (LC-MS) and peptide mapping.
- RNA (Drug Substance) Characterization: These tests ensure the therapeutic RNA is produced correctly, remains stable, and is free of defects. Sequencing checks the nucleotide sequence and size. LC-MS and Capillary Gel Electrophoresis (CGE) are used.
- RNA Purity & Impurities: These tests detect shortened sequences, failed couplings, and other impurities. They also confirm that specific chemical changes, like 2′-O-methyl or phosphorothioate linkages, are present.
- Antibody (Drug Substance) Characterization: This step checks the monoclonal antibody before it is linked to RNA. It looks for fragmentation or clumping. Techniques include SEC, SDS-PAGE, and reduced or non-reduced CE. The tests also profile glycosylation patterns, charge differences, and oxidation levels, using Intact Mass Spectrometry and Ion Exchange Chromatography (IEX).
Final Drug Product (AOC) Purity and Potency
These tests check the finished AOC for breakdown, stability, and leftover materials from the process. They measure any unlinked therapeutic RNA and any antibody that did not bind RNA. High-molecular-weight aggregates are detected using SEC-MALS (Multi-Angle Light Scattering). The tests also confirm that the AOC can bind to its target, such as the transferrin receptor, and deliver the RNA to silence genes. They measure how well the antibody binds its receptor, using Surface Plasmon Resonance (SPR) or ELISA. Cell-based gene knockdown tests show the extent of target mRNA or protein reduction in relevant cell lines, such as muscle cells in myotonic dystrophy.